3 research outputs found
Long-Term Outcome Up To 40 Years after Single Patch Repair of Complete Atrioventricular Septal Defect in Infancy or Childhood
Objectives Patients with repaired complete atrioventricular septal defect (CAVSD) represent an increasing portion of grown-ups with congenital heart disease. For repair of CAVSD, the single-patch technique has been employed first. This technique requires division of the bridging leaflets, thus, among other issues, long-term function of the atrioventricular valves is of particular concern. Methods Between 1978 and 2001, 100 consecutive patients with isolated CAVSD underwent single-patch repair in our institution. Hospital mortality was 11%. Primary endpoints were clinical status, atrioventricular valve function, and freedom from reoperation in long term. Follow-up was obtained contacting the patient and/or caregiver, and the referring cardiologist. Results Eighty-three patients were eligible for long-term follow-up (21.0 +/- 8.7, mean +/- standard deviation [21.5; 2.1-40.0, median; min-max] years after surgical repair). Actual long-term mortality was 3.4%. Quality of life (QoL; self- or caregiver-reported in patients with Down syndrome) was excellent or good in 81%, mild congestive heart failure was present in 16%, moderate in 3.6% as estimated by New York Heart Association classification. Echocardiography revealed normal systolic left ventricular function in all cases. Regurgitation of the right atrioventricular valve was mild in 48%, mild-moderate in 3.6%, and moderate in 1.2%. The left atrioventricular valve was mildly stenotic in 15% and mild to moderately stenotic in 2%; regurgitation was mild in 54%, mild to moderate in 13%, and moderate in 15% of patients. Freedom from left atrioventricular-valve-related reoperation was 95.3, 92.7, and 89.3% after 5, 10, and 30 years, respectively. Permanent pacemaker therapy, as an immediate result of CAVSD repair ( n = 7) or as a result of late-onset sick sinus syndrome ( n = 5), required up to six reoperations in single patients. Freedom from pacemaker-related reoperation was 91.4, 84.4, and 51.5% after 5, 10, and 30 years, respectively. Conclusion Up to 40 years after single-patch repair of CAVSD, clinical status and functional results are promising, particularly, in terms of atrioventricular valve function. Permanent pacemaker therapy results in a life-long need for surgical reinterventions
Urinary Nâterminal proâbrain natriuretic peptide: prognostic value in patients with acute chest pain
Abstract Aims The objective of this study was to investigate the prognostic value of urinary Nâterminal proâbrain natriuretic peptide (NTâproBNP) compared with plasma NTâproBNP in patients presenting with acute chest pain in the emergency department. Methods and results We measured simultaneously plasma and urinary NTâproBNP at admission in 301 patients with acute chest pain. In our cohort, 174 patients suffered from acute coronary syndrome (ACS). A followâup (median of 55 months) was performed regarding the endpoints allâcause mortality and major adverse cardiac events (mortality, congestive heart failure, ACS with the necessity of a coronary intervention, and stroke). Fiftyâfour patients died during followâup; 98 suffered from the combined endpoint. A significant and positive correlation of urinary and plasma NTâproBNP was found (r = 0.87, P < 0.05). Patients with troponin positive ACS had significantly elevated levels of plasma and urinary NTâproBNP compared with those with unstable angina pectoris or chest wall syndrome (each P < 0.05). The highest levels of both biomarkers were found in patients with congestive heart failure (each P < 0.05). According to KaplanâMeier analysis, plasma and urinary NTâproBNP were significant predictors for mortality and the combined endpoint in the whole study cohort and in the subgroup of patients with ACS (each P < 0.05). Regarding Cox regression analysis, plasma and urinary NTâproBNP were independent predictors for mortality and the combined endpoint (each P < 0.05). Conclusions Urinary NTâproBNP seems to provide a significant predictive value regarding the endpoints allâcause mortality and major adverse cardiac events in patients with acute chest pain and those with ACS
Urinary Nâterminal proâbrain natriuretic peptide: prognostic value in patients with acute chest pain
Abstract Aims The objective of this study was to investigate the prognostic value of urinary Nâterminal proâbrain natriuretic peptide (NTâproBNP) compared with plasma NTâproBNP in patients presenting with acute chest pain in the emergency department. Methods and results We measured simultaneously plasma and urinary NTâproBNP at admission in 301 patients with acute chest pain. In our cohort, 174 patients suffered from acute coronary syndrome (ACS). A followâup (median of 55 months) was performed regarding the endpoints allâcause mortality and major adverse cardiac events (mortality, congestive heart failure, ACS with the necessity of a coronary intervention, and stroke). Fiftyâfour patients died during followâup; 98 suffered from the combined endpoint. A significant and positive correlation of urinary and plasma NTâproBNP was found (r = 0.87, P < 0.05). Patients with troponin positive ACS had significantly elevated levels of plasma and urinary NTâproBNP compared with those with unstable angina pectoris or chest wall syndrome (each P < 0.05). The highest levels of both biomarkers were found in patients with congestive heart failure (each P < 0.05). According to KaplanâMeier analysis, plasma and urinary NTâproBNP were significant predictors for mortality and the combined endpoint in the whole study cohort and in the subgroup of patients with ACS (each P < 0.05). Regarding Cox regression analysis, plasma and urinary NTâproBNP were independent predictors for mortality and the combined endpoint (each P < 0.05). Conclusions Urinary NTâproBNP seems to provide a significant predictive value regarding the endpoints allâcause mortality and major adverse cardiac events in patients with acute chest pain and those with ACS